Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Gianpaolo Reboldi
 -- 2319 2024-02-07 09:15:55 |
2 format correct
Catherine Yang
 Meta information modification 2319 2024-02-07 09:24:26 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Patera, F.; Gatticchi, L.; Cellini, B.; Chiasserini, D.; Reboldi, G. Molecular Scenario of Kidney Fibrosis and Oxidative Stress. Encyclopedia. Available online: https://encyclopedia.pub/entry/54836 (accessed on 18 May 2024).
Patera F, Gatticchi L, Cellini B, Chiasserini D, Reboldi G. Molecular Scenario of Kidney Fibrosis and Oxidative Stress. Encyclopedia. Available at: https://encyclopedia.pub/entry/54836. Accessed May 18, 2024.
Patera, Francesco, Leonardo Gatticchi, Barbara Cellini, Davide Chiasserini, Gianpaolo Reboldi. "Molecular Scenario of Kidney Fibrosis and Oxidative Stress" Encyclopedia, https://encyclopedia.pub/entry/54836 (accessed May 18, 2024).
Patera, F., Gatticchi, L., Cellini, B., Chiasserini, D., & Reboldi, G. (2024, February 07). Molecular Scenario of Kidney Fibrosis and Oxidative Stress. In Encyclopedia. https://encyclopedia.pub/entry/54836
Patera, Francesco, et al. "Molecular Scenario of Kidney Fibrosis and Oxidative Stress." Encyclopedia. Web. 07 February, 2024.
Molecular Scenario of Kidney Fibrosis and Oxidative Stress
Edit
This entry is adapted from the peer-reviewed paper 10.3390/biom14010137

Kidney fibrosis, diffused into the interstitium, vessels, and glomerulus, is the main pathologic feature associated with loss of renal function and chronic kidney disease (CKD). Fibrosis may be triggered in kidney diseases by different genetic and molecular insults. 

kidney fibrosis oxidative stress mitochondrial energy imbalance mineralocorticoid signaling

1. Glucose and Mitochondrial Energy Imbalance in Kidney Disease

Filtered glucose can alter the cellular metabolism of endothelial, glomerular, and proximal tubule (PT) cells and progressively contribute to impair kidney function [1][2].
At the kidney level, excessive glucose load, even if transitory, induces massive and long-lasting cellular modifications, like adaptive hypertrophy, glomerular hyperfiltration, rearrangement of metabolic pathways, and epigenomic changes in kidney cells [3][4][5]. For instance, proximal tubular (PT) cells in the presence of glycosuria require an abnormal amount of energy and oxygen consumption for ATP synthesis to sustain continuous glucose reabsorption into the bloodstream through sodium–glucose cotransporters (SGLTs) [6]. This altered energy-metabolism flux generates an oxidative burst that leads to mitochondrial dysfunction by triggering inflammatory and fibrotic pathways, which ultimately determines the decline of the glomerular filtration rate (GFR) and renal scarring [7][8][9].
At the molecular level, PT cells are forced by the excessive glucose availability to overwhelm its catabolism via the glycolytic and mitochondrial oxidative pathways, inducing the generation of damaging levels of reactive oxygen species (ROS) and depleting intracellular content of oxygen. Under normal conditions, PT cells utilize fatty acid oxidation (FAO) as the preferential source for producing ATP, and the impairment of oxidative phosphorylation (OXPHOS) downstream of FAO is thought to be one of the key drivers of tubular injury and fibrinogenesis [10][11]. Notably, positive regulation of FAO transcriptional regulators (e.g., PPARα and PGC-1α) and mediators (e.g., CPT1α) plays a protective role against severe cellular damage in PT cells [12][13][14]. Moreover, the uptake control of free fatty acids (FFAs) via the inhibition of the free fatty acid transporters CD36 or FATP2 in PT cells permits a reduction in the lipotoxicity produced following an excess of lipid accumulation in cells that are unable to efficiently perform FAO [12][15][16][17].
Hyperglycemia-induced ROS overproduction is responsible for a plethora of detrimental effects due to the alteration of the cellular oxidant–antioxidant balance. Indeed, a reduced ROS scavenging ability brings an accumulation of irreversibly modified cellular sugars, lipids, nucleic acids, and proteins that can stimulate secondary metabolisms like the polyol, hexosamine, AGE/RAGE, and protein kinase C (PKC) pathways, which are able to disrupt cellular homeostasis [18][19][20][21][22][23]. These activated pathways induce several downstream signaling events as the activation of an inflammatory response mediated by the nuclear factor-κB (NF-κB) and/or JAK/STAT3 pathways, thus mediating the release of inflammatory cytokines (e.g., TNFα), chemokines, adhesion molecules, and fibrinogenic factors (e.g., TGF-β1) [24][25][26][27]. Additionally, the activity of phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) exerts a tight control over cell proliferation, differentiation, and apoptotic processes by in turn regulating the glycogen synthase 3 β (GSK3β), mTOR (mammalian target of rapamycin), and Forkhead Box Protein O1 (FoxO1) signaling effectors [28][29][30][31]. Nonetheless, the oxidative stress-induced nuclear translocation of the nuclear factor erythroid-2-related factor 2 (Nrf2) transcription factor can promote the expression of antioxidant enzymes while counteracting NF-κB activation, which simultaneously ameliorates cellular defense against oxidative damage and dampens the resulting inflammatory response [32][33][34]. The combination of an augmented inflammatory response, which is responsible for the activation of immune cells and fibroblast-mediated collagen deposition, and a hypertrophic expansion of renal cells altogether contributes to tubular atrophy and glomerular hyperfiltration accompanied by persistent proteinuria and, in the end, loss of kidney functionality.
On the other hand, PT cells of patients with diabetic kidney disease (DKD) exhibit aberrant oxygen consumption that creates a cellular environment characterized by a low oxygen tension and ATP content. Under these conditions, oxygen and energy substrate deprivation can promote the activation of hypoxia-inducible factor 1 α (HIF1α) and of AMP-activated protein kinase (AMPK), which are responsive for oxygen and AMP levels, respectively. HIF-1α is transcription factor that can regulate the expression of the glycolytic enzymes hexokinase-1 (HK1) and phosphofructokinase (PFKL) to promote ATP production with anerobic glycolysis instead of aerobic mitochondrial OXPHOS [35]. AMPK is a modulator of mTOR, a serine/threonine kinase that mediates cell growth control based on the cellular nutrient status [36]. Both HIF-1α and AMPK pathways contribute to fuel the uncontrolled tissue growth and injury accumulation in the PT cells of diabetic individuals with CKD [36].
Therefore, the preservation of mitochondrial function is crucial for the prevention of kidney failure, and it could be achieved by limiting the glucose reuptake mediated by SGLT transporters. The use of SGLT inhibitors represents a potential therapeutic strategy to prevent the establishment of metabolic anomalies, oxidative damage, inflammatory bursts, and hypoxic environments, which are at the basis of renal fibrotic tissue formation and drive DKD progression/severity, at early stages.

2. Glucagon-like Peptide-1 in Kidney Disease

Glucagon-like peptide-1 (GLP-1) is a peptide hormone that plays a critical role in glucose homeostasis and insulin secretion [37]. It is produced from the pro-glucagon gene (GCG), which is subjected to post-translation processing by prohormone convertase enzymes (PCSKs). PCSK1, expressed mainly in intestinal cells and in the brain, cleaves the pro-hormone in GLP-1, while PCSK2 produces a longer peptide that includes both GLP-1 and GLP-2 [37]. Therefore, the production of pro-glucagon peptides is regulated by the tissue-specific expression of proteases, and the intestine and brain are the main organs producing GLP-1 [37]. The effects of GLP-1 are mediated by the interaction the GLP-1 receptor (GLP-1R) that is expressed at high levels in the pancreas [38]. Activation of GLP-1R by GLP-1 induces pleiotropic effects on glucose metabolism, promoting insulin secretion and reducing blood glucose levels. In parallel, GLP-1R activation inhibits the release of glucagon from pancreatic alpha cells, helping the suppression of hepatic glucose production and contributing to the overall reduction in blood glucose levels [38]. The metabolic effects of GLP-1 are not restricted to glucose metabolism but may influence other physiological districts, like the cardiovascular system and the kidneys. Indeed, GLP-1 can stimulate vasodilation via the induction of nitric oxide (NO) production [39], decreasing platelet activation and inflammation and contributing to overall cardiovascular health [39]. In the kidneys, GLP-1 seems to have important functions related to renal protection. GLP-1R is expressed in the kidneys across different cell types [40], and its expression is lower in DKD patients [41]. The nephroprotective effect of GLP-1 does not seem to correlate with glucose lowering. In an animal model of diabetic nephropathy, GLP-1R agonists were able to reduce proteinuria and ameliorate glomerular filtration without modifying blood pressure or body weight [42]. In humans, GLP-1 infusion can increase sodium excretion and improve the glomerular filtration rate [43][44].

3. Mineralocorticoids in Kidney Disease

Aldosterone acts on Na+/K+-ATPase to promote sodium reabsorption, potassium excretion, and water retention, thus leading to hypertension, but it also mediates some untoward pro-inflammatory and pro-fibrotic effects in the kidneys [45]. It is known that in diabetes, hyperglycemia can increase Ang II production, as well as upregulate MR synthesis, thus further worsening tissue damage [46]. Notably, local aldosterone synthesis promotes renal fibrosis by stimulating fibroblast proliferation through growth factor activation, as well as fibronectin production, thus confirming how the hyperactivation of the RAAS system plays a key role on the pathogenesis of DKD.
The action of aldosterone depends on the activation of a nuclear receptor called the mineralocorticoid receptor (MR), and the expression of 11β-hydroxysteroid dehydrogenase type 2 in the cells of the distal nephron is crucial to confer specificity for aldosterone over glucocorticoids [45]. In the resting state, MR localizes in the cell cytosol, bound to heat-shock proteins. Upon aldosterone binding, it translocates to the nucleus, where it binds the hormone-responsive elements to initiate the transcription of target genes. Preclinical data indicate that the molecular effects of MR activation in kidney disease are related to (i) oxidative stress, due to increased ROS production through the induction of NADPH oxidases and/or decreased ROS detoxification through repression of glucose-6-phosphate dehydrogenase; (ii) inflammation, due to increased leucocyte infiltration, pro-inflammatory cytokine production, and adhesion molecule production; and (iii) promotion of fibrosis through the increased production of connective tissue growth factors, leading to the proliferation of fibroblasts and the deposition of the extracellular matrix [47].
All these finding have prompted the targeting of MR using MR antagonists (MRAs). The first MRA approved was spironolactone, but its reduced specificity led to the development of the more selective eplerenone, which attenuated renal fibrosis and reduced oxidative stress in preclinical studies [48]. Recently, to improve the efficacy and reduce the side effects of MRAs, new-generation MRAs with a non-steroidal structure have been developed. The most effective is finerenone, which behaves as an inverse agonist and inhibits cofactor recruitment to MRs in the ligand-free state [49].

4. HIF-PHD Axis: Molecular Mechanism and Its Role in Kidney Diseases

Hypoxia-induced factor (HIF) is the master regulator of adaptative responses to reduced oxygen availability [50]. HIF is a heterodimeric protein complex generally composed of two proteins; the first one, HIF-1 alpha (HIF1α), is codified by the HIF1A gene, while the second subunit, HIF-1 beta (HIF1β), or aryl hydrocarbon receptor nuclear translocator protein, is codified by the ARNT gene [51] and is expressed constitutively. Upon heterodimerization, the complex has transcriptional activity and binds to hypoxia response elements (HREs) within the promoters of many different downstream targets, activating their transcription [50]. Major targets of the HIF complex are genes involved in angiogenesis, red blood cell development, glycolysis, oxidative stress, and other genes involved in oxygen sensing and metabolic conditioning to hypoxia [52].
The HIF complex is regulated in a variety of ways. A major pathway is the PHD–VHL–HIF axis, where, besides HIF, prolyl hydroxylase domain-containing proteins (PHDs) and Von Hippel–Lindau tumor suppressor (VHL or pVHL) are the key proteins regulating HIF activation/deactivation. In normoxia, HIF1α is hydroxylated by PHDs, and particularly by PHD2, an α-ketoglutarate/2-oxoglutarate-dependent dioxygenase that contains Fe2+ in the active site. Hydroxylated HIF can interact with VHL, acting as a substrate-recognition subunit of the Cullin-RING E3 ubiquitin ligase complex and therefore targeting HIF for proteasomal degradation [53]. In hypoxia, hydroxylation is inhibited, thereby decreasing HIF degradation and promoting the formation of the heterodimeric complex HIF1α/HIF1β that can activate transcription of target genes in the nucleus [50].
HIF is also regulated by another dioxygenase called factor-inhibiting HIF-1 (FIH1). FIH1 can hydroxylate an asparagine residue on HIF1α, preventing interaction with the p300 and CBP proteins which act as coactivators of the transcriptional heterodimeric complex, eventually inhibiting the transcription of hypoxia-related genes [54]. FIH1 has more affinity for O2 when compared to members of the PHD family; therefore, it is still active when oxygen levels are very low [55]. Combined regulation by PHD proteins and FIH1 can provide a dynamic response to hypoxia within a wide range of oxygen tensions.
In the kidney, hypoxia represents one of the main consequences of fibrosis, since expansion of fibrotic tissue is associated with the loss of peritubular capillaries, reduced blood flow, and renal anemia [56][57]. In addition, kidneys show low oxygen tension when compared to other organs [58] and display an increase in oxygen demand according to several models mimicking different pathologies with renal involvement, such as diabetes and hypertension [59][60]. These studies underscore the dynamic regulation of oxygen demand in the kidney to supply enough energy for cellular activities such as transport, electrolyte regulation, and several other processes through the aerobic metabolism [61].
Three isoforms of HIFα are expressed in the kidney: HIF-1α, HIF-2α, and HIF-3α. Studies have mainly investigated the roles of HIF-1α and HIF-2α in the kidney. The two isoforms seem to have a different pattern of expression in kidney cells, where HIF-1α is enriched in tubular cells (TECs), while HIF-2α is mainly expressed in endothelial cells and interstitial fibroblasts [62]. However, recent single-cell atlas data have also shown relatively high expression of HIF-2α in TEC cells at the mRNA level [63]. Both isoforms have shown clear associations with renal fibrosis. In a model of cisplatin-induced renal fibrosis, HIF-1α was increased and promoted at the onset of the pathology, activating NOTCH-1 signaling [64]. Other studies have shown that HIF-1α is able to activate a series of pro-fibrotic pathways, including secretion of inflammatory mediators such as IL-1β and TNF-α, induction of epithelial–mesenchymal transition (EMT), and vascular remodeling [65]. HIF-2α is also prominently involved in renal fibrosis. In a unilateral ureteral obstruction (UUO) model of mice, knock-out of HIF-2α attenuated renal fibrosis through a mechanism involving sirtuin-1 (SIRT1) [66]. On the other hand, it has been shown that long-term activation of HIF-2α may alter the course of renal fibrosis, improving renal function and decreasing several EMT markers [67].
Xue Li and coworkers [68] showed that in a mouse model of tubular proximal cells, damage induced by folic acid (FA) and relative mitochondrial failure, treatment with the HIF stabilizer Roxadustat prior to FA administration reduced cell apoptosis, stabilized intercellular junctions, and promoted the expression of aquaporin 1 (AQP1) and aquaporin 2 (AQP2). Moreover, interstitial inflammatory cell infiltration after FA injection was reduced as well as collagen deposition. The concentration of HIF-1α in mice treated with Roxadustat was elevated until day 3 from the FA injection and then decreased, while in the control group, it remained elevated until day 7, the time at which the histologic signs of tubular toxicity were evaluated. In the latter group, persistently elevated levels of HIF-1α were related to mitochondria fragmentation and reduction in crest expression, a sign of metabolic suffering. As a consequence, the intracellular levels of ATP decreased in the control group, while the group treated with Roxadustat showed stable ATP levels and decreased ROS levels. A meaningful finding was that in the damaged tubular cells of the non-treated group, the mitochondrial pattern shifted from a fusion pattern to a fission pattern, as demonstrated by the hyperexpression of fission proteins such as FIS 1 e Drp 1 and the lower expression of fusion proteins such as Opa1 and Mfn1. In the Roxadustat group, the pattern shifted to a fusion pattern, ameliorating the aerobic metabolism [68].
Taken together, these studies show how regulation of HIF activation and/or expression may directly influence the development of pro-fibrotic pathways, even though contrasting results are often reported and may be associated to different outcomes for renal health [69].

References

  1. Johansen, K.L.; Chertow, G.M.; Foley, R.N.; Gilbertson, D.T.; Herzog, C.A.; Ishani, A.; Israni, A.K.; Ku, E.; Kurella Tamura, M.; Li, S.; et al. US Renal Data System 2020 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am. J. Kidney Dis. 2021, 77, A7–A8.
  2. Mohandes, S.; Doke, T.; Hu, H.; Mukhi, D.; Dhillon, P.; Susztak, K. Molecular pathways that drive diabetic kidney disease. J. Clin. Investig. 2023, 133, e165654.
  3. El-Osta, A.; Brasacchio, D.; Yao, D.; Pocai, A.; Jones, P.L.; Roeder, R.G.; Cooper, M.E.; Brownlee, M. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J. Exp. Med. 2008, 205, 2409–2417.
  4. Chen, Z.; Miao, F.; Paterson, A.D.; Lachin, J.M.; Zhang, L.; Schones, D.E.; Wu, X.; Wang, J.; Tompkins, J.D.; Genuth, S.; et al. Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort. Proc. Natl. Acad. Sci. USA 2016, 113, E3002–E3011.
  5. Gilbert, R.E.; Huang, Q.; Thai, K.; Advani, S.L.; Lee, K.; Yuen, D.A.; Connelly, K.A.; Advani, A. Histone deacetylase inhibition attenuates diabetes-associated kidney growth: Potential role for epigenetic modification of the epidermal growth factor receptor. Kidney Int. 2011, 79, 1312–1321.
  6. Ahmad, M.; Abramovich, I.; Agranovich, B.; Nemirovski, A.; Gottlieb, E.; Hinden, L.; Tam, J. Kidney Proximal Tubule GLUT2-More than Meets the Eye. Cells 2022, 12, 94.
  7. Granata, S.; Zaza, G.; Simone, S.; Villani, G.; Latorre, D.; Pontrelli, P.; Carella, M.; Schena, F.P.; Grandaliano, G.; Pertosa, G. Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genom. 2009, 10, 388.
  8. Andres-Hernando, A.; Lanaspa, M.A.; Kuwabara, M.; Orlicky, D.J.; Cicerchi, C.; Bales, E.; Garcia, G.E.; Roncal-Jimenez, C.A.; Sato, Y.; Johnson, R.J. Obesity causes renal mitochondrial dysfunction and energy imbalance and accelerates chronic kidney disease in mice. Am. J. Physiol. Renal Physiol. 2019, 317, F941–F948.
  9. Doke, T.; Susztak, K. The multifaceted role of kidney tubule mitochondrial dysfunction in kidney disease development. Trends Cell Biol. 2022, 32, 841–853.
  10. Balaban, R.S.; Mandel, L.J. Metabolic substrate utilization by rabbit proximal tubule. An NADH fluorescence study. Am. J. Physiol. 1988, 254, F407–F416.
  11. Thome, T.; Kumar, R.A.; Burke, S.K.; Khattri, R.B.; Salyers, Z.R.; Kelley, R.C.; Coleman, M.D.; Christou, D.D.; Hepple, R.T.; Scali, S.T.; et al. Impaired muscle mitochondrial energetics is associated with uremic metabolite accumulation in chronic kidney disease. JCI Insight 2020, 6, e139826.
  12. Kang, H.M.; Ahn, S.H.; Choi, P.; Ko, Y.A.; Han, S.H.; Chinga, F.; Park, A.S.; Tao, J.; Sharma, K.; Pullman, J.; et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat. Med. 2015, 21, 37–46.
  13. Han, S.H.; Wu, M.Y.; Nam, B.Y.; Park, J.T.; Yoo, T.H.; Kang, S.W.; Park, J.; Chinga, F.; Li, S.Y.; Susztak, K. PGC-1α Protects from Notch-Induced Kidney Fibrosis Development. J. Am. Soc. Nephrol. 2017, 28, 3312–3322.
  14. Miguel, V.; Tituana, J.; Herrero, J.I.; Herrero, L.; Serra, D.; Cuevas, P.; Barbas, C.; Puyol, D.R.; Marquez-Exposito, L.; Ruiz-Ortega, M.; et al. Renal tubule Cpt1a overexpression protects from kidney fibrosis by restoring mitochondrial homeostasis. J. Clin. Investig. 2021, 131, e140695.
  15. Khan, S.; Cabral, P.D.; Schilling, W.P.; Schmidt, Z.W.; Uddin, A.N.; Gingras, A.; Madhavan, S.M.; Garvin, J.L.; Schelling, J.R. Kidney Proximal Tubule Lipoapoptosis Is Regulated by Fatty Acid Transporter-2 (FATP2). J. Am. Soc. Nephrol. 2018, 29, 81–91.
  16. Khan, S.; Gaivin, R.; Abramovich, C.; Boylan, M.; Calles, J.; Schelling, J.R. Fatty acid transport protein-2 regulates glycemic control and diabetic kidney disease progression. JCI Insight 2020, 5, e136845.
  17. Chen, Y.; Yan, Q.; Lv, M.; Song, K.; Dai, Y.; Huang, Y.; Zhang, L.; Zhang, C.; Gao, H. Involvement of FATP2-mediated tubular lipid metabolic reprogramming in renal fibrogenesis. Cell Death Dis. 2020, 11, 994.
  18. Tilton, R.G.; Chang, K.; Nyengaard, J.R.; Van den Enden, M.; Ido, Y.; Williamson, J.R. Inhibition of sorbitol dehydrogenase. Effects on vascular and neural dysfunction in streptozocin-induced diabetic rats. Diabetes 1995, 44, 234–242.
  19. Singh, L.P.; Cheng, D.W.; Kowluru, R.; Levi, E.; Jiang, Y. Hexosamine induction of oxidative stress, hypertrophy and laminin expression in renal mesangial cells: Effect of the anti-oxidant alpha-lipoic acid. Cell Biochem. Funct. 2007, 25, 537–550.
  20. Garg, S.S.; Gupta, J. Polyol pathway and redox balance in diabetes. Pharmacol. Res. 2022, 182, 106326.
  21. Ma, X.; Ma, J.; Leng, T.; Yuan, Z.; Hu, T.; Liu, Q.; Shen, T. Advances in oxidative stress in pathogenesis of diabetic kidney disease and efficacy of TCM intervention. Ren. Fail. 2023, 45, 2146512.
  22. Kang, Q.; Yang, C. Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol. 2020, 37, 101799.
  23. Zhou, X.; Liu, Z.; Ying, K.; Wang, H.; Liu, P.; Ji, X.; Chi, T.; Zou, L.; Wang, S.; He, Z. WJ-39, an Aldose Reductase Inhibitor, Ameliorates Renal Lesions in Diabetic Nephropathy by Activating Nrf2 Signaling. Oxid. Med. Cell Longev. 2020, 2020, 7950457.
  24. Hofmann, M.A.; Schiekofer, S.; Isermann, B.; Kanitz, M.; Henkels, M.; Joswig, M.; Treusch, A.; Morcos, M.; Weiss, T.; Borcea, V.; et al. Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-kappaB. Diabetologia 1999, 42, 222–232.
  25. Yu, J.; Wu, H.; Liu, Z.Y.; Zhu, Q.; Shan, C.; Zhang, K.Q. Advanced glycation end products induce the apoptosis of and inflammation in mouse podocytes through CXCL9-mediated JAK2/STAT3 pathway activation. Int. J. Mol. Med. 2017, 40, 1185–1193.
  26. Zoccali, C.; Mallamaci, F. Nonproteinuric progressive diabetic kidney disease. Curr. Opin. Nephrol. Hypertens. 2019, 28, 227–232.
  27. Zhu, M.; Wang, H.; Chen, J.; Zhu, H. Sinomenine improve diabetic nephropathy by inhibiting fibrosis and regulating the JAK2/STAT3/SOCS1 pathway in streptozotocin-induced diabetic rats. Life Sci. 2021, 265, 118855.
  28. Li, W.; Wang, Q.; Du, M.; Ma, X.; Wu, L.; Guo, F.; Zhao, S.; Huang, F.; Wang, H.; Qin, G. Effects of overexpressing FoxO1 on apoptosis in glomeruli of diabetic mice and in podocytes cultured in high glucose medium. Biochem. Biophys. Res. Commun. 2016, 478, 612–617.
  29. Ying, C.; Mao, Y.; Chen, L.; Wang, S.; Ling, H.; Li, W.; Zhou, X. Bamboo leaf extract ameliorates diabetic nephropathy through activating the AKT signaling pathway in rats. Int. J. Biol. Macromol. 2017, 105, 1587–1594.
  30. Lu, Q.; Wang, W.W.; Zhang, M.Z.; Ma, Z.X.; Qiu, X.R.; Shen, M.; Yin, X.X. ROS induces epithelial-mesenchymal transition via the TGF-beta1/PI3K/Akt/mTOR pathway in diabetic nephropathy. Exp. Ther. Med. 2019, 17, 835–846.
  31. Li, C.; Guan, X.M.; Wang, R.Y.; Xie, Y.S.; Zhou, H.; Ni, W.J.; Tang, L.Q. Berberine mitigates high glucose-induced podocyte apoptosis by modulating autophagy via the mTOR/P70S6K/4EBP1 pathway. Life Sci. 2020, 243, 117277.
  32. Jiang, T.; Huang, Z.; Lin, Y.; Zhang, Z.; Fang, D.; Zhang, D.D. The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes 2010, 59, 850–860.
  33. Zheng, H.; Whitman, S.A.; Wu, W.; Wondrak, G.T.; Wong, P.K.; Fang, D.; Zhang, D.D. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 2011, 60, 3055–3066.
  34. Alshehri, A.S. Kaempferol attenuates diabetic nephropathy in streptozotocin-induced diabetic rats by a hypoglycaemic effect and concomitant activation of the Nrf-2/Ho-1/antioxidants axis. Arch. Physiol. Biochem. 2023, 129, 984–997.
  35. Cai, T.; Ke, Q.; Fang, Y.; Wen, P.; Chen, H.; Yuan, Q.; Luo, J.; Zhang, Y.; Sun, Q.; Lv, Y.; et al. Sodium-glucose cotransporter 2 inhibition suppresses HIF-1alpha-mediated metabolic switch from lipid oxidation to glycolysis in kidney tubule cells of diabetic mice. Cell Death Dis. 2020, 11, 390.
  36. Decleves, A.E.; Mathew, A.V.; Cunard, R.; Sharma, K. AMPK mediates the initiation of kidney disease induced by a high-fat diet. J. Am. Soc. Nephrol. 2011, 22, 1846–1855.
  37. Alicic, R.Z.; Cox, E.J.; Neumiller, J.J.; Tuttle, K.R. Incretin drugs in diabetic kidney disease: Biological mechanisms and clinical evidence. Nat. Rev. Nephrol. 2021, 17, 227–244.
  38. Graaf, C.; Donnelly, D.; Wootten, D.; Lau, J.; Sexton, P.M.; Miller, L.J.; Ahn, J.M.; Liao, J.; Fletcher, M.M.; Yang, D.; et al. Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes. Pharmacol. Rev. 2016, 68, 954–1013.
  39. Barale, C.; Buracco, S.; Cavalot, F.; Frascaroli, C.; Guerrasio, A.; Russo, I. Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation. Thromb. Haemost. 2017, 117, 1115–1128.
  40. Pyke, C.; Heller, R.S.; Kirk, R.K.; Orskov, C.; Reedtz-Runge, S.; Kaastrup, P.; Hvelplund, A.; Bardram, L.; Calatayud, D.; Knudsen, L.B. GLP-1 receptor localization in monkey and human tissue: Novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014, 155, 1280–1290.
  41. Fan, Y.; Yi, Z.; D’Agati, V.D.; Sun, Z.; Zhong, F.; Zhang, W.; Wen, J.; Zhou, T.; Li, Z.; He, L.; et al. Comparison of Kidney Transcriptomic Profiles of Early and Advanced Diabetic Nephropathy Reveals Potential New Mechanisms for Disease Progression. Diabetes 2019, 68, 2301–2314.
  42. Kodera, R.; Shikata, K.; Kataoka, H.U.; Takatsuka, T.; Miyamoto, S.; Sasaki, M.; Kajitani, N.; Nishishita, S.; Sarai, K.; Hirota, D.; et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011, 54, 965–978.
  43. Gutzwiller, J.P.; Tschopp, S.; Bock, A.; Zehnder, C.E.; Huber, A.R.; Kreyenbuehl, M.; Gutmann, H.; Drewe, J.; Henzen, C.; Goeke, B.; et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J. Clin. Endocrinol. Metab. 2004, 89, 3055–3061.
  44. Muskiet, M.H.A.; Tonneijck, L.; Smits, M.M.; van Baar, M.J.B.; Kramer, M.H.H.; Hoorn, E.J.; Joles, J.A.; van Raalte, D.H. GLP-1 and the kidney: From physiology to pharmacology and outcomes in diabetes. Nat. Rev. Nephrol. 2017, 13, 605–628.
  45. Rocha, R.; Stier, C.T., Jr.; Kifor, I.; Ochoa-Maya, M.R.; Rennke, H.G.; Williams, G.H.; Adler, G.K. Aldosterone: A mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000, 141, 3871–3878.
  46. Kawanami, D.; Takashi, Y.; Muta, Y.; Oda, N.; Nagata, D.; Takahashi, H.; Tanabe, M. Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease. Front. Pharmacol. 2021, 12, 754239.
  47. Barrera-Chimal, J.; Girerd, S.; Jaisser, F. Mineralocorticoid receptor antagonists and kidney diseases: Pathophysiological basis. Kidney Int. 2019, 96, 302–319.
  48. Chen, H.; Sun, F.; Zhong, X.; Shao, Y.; Yoshimura, A.; Liu, Y. Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress. Kidney Blood Press. Res. 2013, 37, 557–566.
  49. Kolkhof, P.; Jaisser, F.; Kim, S.Y.; Filippatos, G.; Nowack, C.; Pitt, B. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside. Handb. Exp. Pharmacol. 2017, 243, 271–305.
  50. Semenza, G.L. Oxygen sensing, homeostasis, and disease. N. Engl. J. Med. 2011, 365, 537–547.
  51. Wang, G.L.; Jiang, B.H.; Rue, E.A.; Semenza, G.L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA 1995, 92, 5510–5514.
  52. Semenza, G.L. Oxygen homeostasis. Wiley Interdiscip. Rev. Syst. Biol. Med. 2010, 2, 336–361.
  53. Cornelius, R.J.; Ferdaus, M.Z.; Nelson, J.W.; McCormick, J.A. Cullin-Ring ubiquitin ligases in kidney health and disease. Curr. Opin. Nephrol. Hypertens. 2019, 28, 490–497.
  54. Kaelin, W.G. Proline hydroxylation and gene expression. Annu. Rev. Biochem. 2005, 74, 115–128.
  55. Stolze, I.P.; Tian, Y.M.; Appelhoff, R.J.; Turley, H.; Wykoff, C.C.; Gleadle, J.M.; Ratcliffe, P.J. Genetic analysis of the role of the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (FIH) in regulating hypoxia-inducible factor (HIF) transcriptional target genes . J. Biol. Chem. 2004, 279, 42719–42725.
  56. Ohashi, R.; Shimizu, A.; Masuda, Y.; Kitamura, H.; Ishizaki, M.; Sugisaki, Y.; Yamanaka, N. Peritubular capillary regression during the progression of experimental obstructive nephropathy. J. Am. Soc. Nephrol. 2002, 13, 1795–1805.
  57. Astor, B.C.; Muntner, P.; Levin, A.; Eustace, J.A.; Coresh, J. Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (1988–1994). Arch. Intern. Med. 2002, 162, 1401–1408.
  58. Hirakawa, Y.; Tanaka, T.; Nangaku, M. Renal Hypoxia in CKD. Pathophysiology and Detecting Methods. Front. Physiol. 2017, 8, 99.
  59. Korner, A.; Eklof, A.C.; Celsi, G.; Aperia, A. Increased renal metabolism in diabetes. Mechanism and functional implications. Diabetes 1994, 43, 629–633.
  60. Adler, S.; Huang, H. Impaired regulation of renal oxygen consumption in spontaneously hypertensive rats. J. Am. Soc. Nephrol. 2002, 13, 1788–1794.
  61. Alsahli, M.; Gerich, J.E. Renal glucose metabolism in normal physiological conditions and in diabetes. Diabetes Res. Clin. Pract. 2017, 133, 1–9.
  62. Shu, S.; Wang, Y.; Zheng, M.; Liu, Z.; Cai, J.; Tang, C.; Dong, Z. Hypoxia and Hypoxia-Inducible Factors in Kidney Injury and Repair. Cells 2019, 8, 207.
  63. Karlsson, M.; Zhang, C.; Mear, L.; Zhong, W.; Digre, A.; Katona, B.; Sjostedt, E.; Butler, L.; Odeberg, J.; Dusart, P.; et al. A single-cell type transcriptomics map of human tissues. Sci. Adv. 2021, 7, eabh2169.
  64. Zhao, H.; Han, Y.; Jiang, N.; Li, C.; Yang, M.; Xiao, Y.; Wei, L.; Xiong, X.; Yang, J.; Tang, C.; et al. Effects of HIF-1alpha on renal fibrosis in cisplatin-induced chronic kidney disease. Clin. Sci. 2021, 135, 1273–1288.
  65. Wei, X.; Hou, Y.; Long, M.; Jiang, L.; Du, Y. Molecular mechanisms underlying the role of hypoxia-inducible factor-1 alpha in metabolic reprogramming in renal fibrosis. Front. Endocrinol. 2022, 13, 927329.
  66. Li, P.; Liu, Y.; Qin, X.; Chen, K.; Wang, R.; Yuan, L.; Chen, X.; Hao, C.; Huang, X. SIRT1 attenuates renal fibrosis by repressing HIF-2alpha. Cell Death Discov. 2021, 7, 59.
  67. Kim, D.A.; Lee, M.R.; Oh, H.J.; Kim, M.; Kong, K.H. Effects of long-term tubular HIF-2alpha overexpression on progressive renal fibrosis in a chronic kidney disease model. BMB Rep. 2023, 56, 196–201.
  68. Li, X.; Jiang, B.; Zou, Y.; Zhang, J.; Fu, Y.Y.; Zhai, X.Y. Roxadustat (FG-4592) Facilitates Recovery from Renal Damage by Ameliorating Mitochondrial Dysfunction Induced by Folic Acid. Front. Pharmacol. 2021, 12, 788977.
  69. Deshmukh, A.B.; Patel, J.K.; Prajapati, A.R.; Shah, S. Perspective in chronic kidney disease: Targeting hypoxia-inducible factor (HIF) as potential therapeutic approach. Ren. Fail. 2012, 34, 521–532.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Urology & Nephrology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Francesco Patera
,
Leonardo Gatticchi
,
Barbara Cellini
,
Davide Chiasserini
,
Gianpaolo Reboldi
View Times: 141
Revisions: 2 times (View History)
Update Date: 07 Feb 2024
Table of Contents
    1000/1000
    Hot Most Recent
    Feedback